CHATSWORTH, Calif., March 11, 2010 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of urinalysis systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that it will be presenting at Sidoti & Company's 14th Annual Emerging Growth Institutional Investor Forum at 1:30 p.m. Eastern time on Wednesday, March 24, 2010 at The Grand Hyatt Hotel in New York City. Cesar Garcia, IRIS Chairman, President and Chief Executive Officer, will present an overview of the Company followed by Q&A. A copy of the presentation will be available on the Company's web site at www.proiris.com.
About IRIS International, Inc.
IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,600 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company is developing molecular diagnostic tests based on its Nucleic Acid Detection Immunoassay, or NADiA®, platform, with applications in oncology and infectious disease. For more information visit www.proiris.com.